Tempest Therapeutics Inc

NASDAQ:TPST   3:59:54 PM EDT
2.23
-0.18 (-7.47%)
Products, Regulatory

Tempest Reports Positive Tpst-1120 Clinical Data From Phase 1 Trial In Patients With Advanced Solid Tumors At 2022 Asco Annual Meeting

Published: 05/26/2022 23:41 GMT
Tempest Therapeutics Inc (TPST) - Tempest Reports Positive Tpst-1120 Clinical Data From Phase 1 Trial in Patients With Advanced Solid Tumors at 2022 Asco Annual Meeting.
Tempest Therapeutics Inc - Recist Responses Observed in Io-refractory Patients and in Io-resistant Indications.
Tempest Therapeutics Inc - Tpst-1120 Was Well-tolerated Both As a Monotherapy and in Combination With Nivolumab.
Tempest Therapeutics Inc - Randomized Global Phase 1b/2 Study is Ongoing in Previously Untreated Patients With Hepatocellular Carcinoma.